Genetic Stratification of Age‐Dependent Parkinson's Disease Risk by Polygenic Hazard Score

Parkinson's disease (PD) is a highly age‐related disorder, where common genetic risk variants affect both disease risk and age at onset. A statistical approach that integrates these effects across all common variants may be clinically useful for individual risk stratification. A polygenic hazard score methodology, leveraging a time‐to‐event framework, has recently been successfully applied in other age‐related disorders.

[1]  R. Barker,et al.  Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson’s disease , 2021, Nature Genetics.

[2]  F. Collins,et al.  Precision medicine in 2030—seven ways to transform healthcare , 2021, Cell.

[3]  K. D. Sørensen,et al.  Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer , 2021, Prostate cancer and prostatic diseases.

[4]  O. Andreassen,et al.  Sex-dependent autosomal effects on clinical progression of Alzheimer's disease. , 2020, Brain : a journal of neurology.

[5]  C. Kooperberg,et al.  Improving reporting standards for polygenic scores in risk prediction studies , 2020, Nature.

[6]  Jack A. Taylor,et al.  African‐specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer , 2020, medRxiv.

[7]  O. Andreassen,et al.  Age dependence of modern clinical risk groups for localized prostate cancer—A population‐based study , 2020, Cancer.

[8]  Sonja W. Scholz,et al.  Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies , 2019, The Lancet Neurology.

[9]  D. Hernandez,et al.  Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts , 2019, Movement disorders : official journal of the Movement Disorder Society.

[10]  K. D. Sørensen,et al.  Polygenic hazard score is associated with prostate cancer in multi-ethnic populations , 2019, Nature Communications.

[11]  L. Wilkins Genetic risk of Parkinson disease and progression: An analysis of 13 longitudinal cohorts , 2019, Neurology: Genetics.

[12]  R. Barker,et al.  Genetic analysis of Mendelian mutations in a large UK population-based Parkinson’s disease study , 2019, Brain : a journal of neurology.

[13]  Ali Amin Al Olama,et al.  The effect of sample size on polygenic hazard models for prostate cancer , 2019, bioRxiv.

[14]  L. Sugrue,et al.  What Are Polygenic Scores and Why Are They Important? , 2019, JAMA.

[15]  Sonja W. Scholz,et al.  Parkinson's disease age at onset genome‐wide association study: Defining heritability, genetic loci, and α‐synuclein mechanisms , 2019, Movement disorders : official journal of the Movement Disorder Society.

[16]  C. Tanner,et al.  Concordance for Parkinson's disease in twins: A 20‐year update , 2019, Annals of neurology.

[17]  O. Andreassen,et al.  A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data , 2019, Cancer Epidemiology, Biomarkers & Prevention.

[18]  Yoshihiro Kokubo,et al.  Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[19]  M. Nalls,et al.  Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson’s disease , 2018, Journal of Medical Genetics.

[20]  O. Andreassen,et al.  Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts , 2018, British Medical Journal.

[21]  Lilah M. Besser,et al.  Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score , 2017, PLoS medicine.

[22]  W. Rocca,et al.  Time Trends in the Incidence of Parkinson Disease. , 2016, JAMA neurology.

[23]  N. Jetté,et al.  The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis , 2016, Neuroepidemiology.

[24]  D. Hernandez,et al.  Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI) , 2016, Movement disorders : official journal of the Movement Disorder Society.

[25]  M. Toft,et al.  Cumulative genetic risk and age at onset in Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[26]  Margaret Sutherland,et al.  Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study , 2015, The Lancet Neurology.

[27]  J. Olsen,et al.  Impact of Parkinson's disease risk loci on age at onset , 2015, Movement disorders : official journal of the Movement Disorder Society.

[28]  Valentina Escott-Price,et al.  Genetic risk and age in Parkinson's disease: Continuum not stratum , 2015, Movement disorders : official journal of the Movement Disorder Society.

[29]  Chuong B. Do,et al.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.

[30]  R. Barker,et al.  The incidence of Parkinson's disease in the North-East of England. , 2014, Age and ageing.

[31]  S. Sawcer,et al.  Systematic Review and UK‐Based Study of PARK2 (parkin), PINK1, PARK7 (DJ‐1) and LRRK2 in early‐onset Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[32]  C. Sampaio,et al.  Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. , 2010, Parkinsonism & related disorders.

[33]  L. Forsgren,et al.  Incidence of Parkinson's disease and parkinsonism in northern Sweden: A population‐based study , 2010, Movement disorders : official journal of the Movement Disorder Society.

[34]  Gordon Johnston,et al.  Statistical Models and Methods for Lifetime Data , 2003, Technometrics.